Morgan Stanley & Co. LLC recently announced the acquisition of new stake in I-Mab ADR (NASDAQ:IMAB). The institutional investor has increased its shareholding in the Healthcare company by 123.04% to 0.99 million shares with purchase of 0.54 million shares. This fresh investment now brings its stake to 1.18% valued currently at $1.54 million. In addition, UBS Securities LLC raised its holdings by 20894.0 to 0.56 million shares.
With over 0.46 million I-Mab ADR (IMAB) shares trading Friday and a closing price of $1.55 on the day, the dollar volume was approximately $0.71 million. The shares have shown a negative half year performance of -49.35% and its price on 12/22/23 lost nearly -0.64%. Currently, there are 82.27M common shares owned by the public and among those 81.69M shares have been available to trade.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The top 3 mutual fund holders in I-Mab ADR are iShares Biotechnology ETF, Abaris Emerging Markets Equity, and Saint Olive Gestion BSO Bio Sante. iShares Biotechnology ETF owns 0.4 million shares of the company’s stock, all valued at over $0.62 million. The company sold 2214.0 shares recently to bring their total holdings to about 0.48% of the shares outstanding. Saint Olive Gestion BSO Bio Sante bought 80000.0 shares to bring its total holdings to over 80000.0 shares at a value of $0.12 million. Saint Olive Gestion BSO Bio Sante now owns shares totaling to 0.10% of the shares outstanding.
Shares of I-Mab ADR (NASDAQ: IMAB) opened at $1.53, down -$0.03 from a prior closing price of $1.56. However, the script later moved the day high at 1.6400, down -0.64%. The company’s stock has a 5-day price change of 11.51% and 21.09% over the past three months. IMAB shares are trading -62.92% year to date (YTD), with the 12-month market performance down to -57.06% lower. It has a 12-month low price of $1.16 and touched a high of $7.67 over the same period. IMAB has an average intraday trading volume of 594.56K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 1.89%, 3.98%, and -35.79% respectively.
Institutional ownership of I-Mab ADR (NASDAQ: IMAB) shares accounts for 31.22% of the company’s 82.27M shares outstanding. Mutual fund holders own 1.70%, while other institutional holders and individual stakeholders account for 23.09% and — respectively.
It has a market capitalization of $126.94M and a beta (3y monthly) value of 1.06. Price movements for the stock have been influenced by the stock’s volatility, which stands at 10.12% over the week and 8.41% over the month.
Analysts forecast that I-Mab ADR (IMAB) will achieve an EPS of $0 for the current quarter, $0 for the next quarter and $0 for 2021. The lowest estimate earnings-per-share for the quarter is $0 while analysts give the company a high EPS estimate of $0. Earnings per share for the fiscal year are expected to increase by 4.50%, and -12.90% over the next financial year. EPS should grow at an annualized rate of 26.00% over the next five years, compared to -42.85% over the past 5-year period.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 2 brokerage firm advisors rate I-Mab ADR (IMAB) as a “Strong Buy” at a consensus score of 1.00. Specifically, 2 Wall Street analysts polled rate the stock as a buy, while 0 of the 2 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the IMAB, a number of firms have released research notes about the stock. Siebert Williams Shank stated their Buy rating for the stock in a research note on December 09, 2021, with the firm’s price target at $96.
